Previous 10 | Next 10 |
2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...
2024-03-05 22:43:45 ET Summary Dan Loeb's 13F portfolio value increased to $6.64B this quarter, with the top three holdings accounting for ~37% of the portfolio. Third Point returned 3.4% in 2023 compared to 26.3% for the S&P 500 Index. New stakes include Fleetcor Tech, Ve...
BioMarin Scheduled to Participate in March Investor Conferences PR Newswire - Cowen 44 th Annual Healthcare Conference on March 5 - Leerink Partners Global Biopharma Conference on March 11 - ...
2024-02-29 11:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-23 13:30:03 ET Cantor Fitzgerald analyst issues UNDERPERFORM recommendation for BMRN on February 23, 2024 01:01PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $91.97 at issue of the analyst recommendation. The overall analyst cons...
2024-02-22 21:08:06 ET BioMarin Pharmaceutical, Inc. (BMRN) Q4 2023 Earnings Conference Call February 22, 2024, 04:30 PM ET Company Participants Traci McCarty - Head of Investor Relations Alexander Hardy - President and Chief Executive Officer Henry Fuchs - Presi...
2024-02-22 16:07:42 ET More on BioMarin Pharmaceutical BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest? BioMarin Pharmaceutical Q4 2023 Earnings Preview Paul Singer's Elliott Management adds ETSY, CCI, MTCH; offloads NI, ARM, NE See...
BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024 PR Newswire Total FY'23 Revenues of $2.42 Billion (+15% Y/Y and +20% Y/Y at Constant Currency); GAAP Diluted Earnings per Share of $0.87 (+16% Y/Y...
2024-02-21 17:20:47 ET More on BioMarin Pharmaceutical BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest? Paul Singer's Elliott Management adds ETSY, CCI, MTCH; offloads NI, ARM, NE BioMarin may be M&A target with activist Elliott pact - ...
2024-02-18 08:20:00 ET Despite a holiday-shortened week, investors have their plates full with a diverse range of earnings reports across various sectors. Tech leaders NVIDIA ( NASDAQ: NVDA ) and Palo Alto Networks ( NASDAQ: PANW ) will be in focus, alongside retail gian...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 14:15:03 ET Scotiabank analyst issues UNDERPERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus : BU...
2024-06-27 14:15:02 ET Wells Fargo analyst issues SECTOR PERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Sector Perform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus...